Stanford University School of Medicine, Department of Medicine, Division of Endocrinology, Stanford, California 94305-5103, USA.
J Clin Endocrinol Metab. 2010 Apr;95(4):1851-5. doi: 10.1210/jc.2009-1628. Epub 2010 Feb 4.
Severe hypoglycemia after Roux-en-Y gastric bypass surgery (RYGB) is an increasingly recognized condition, characterized by neuroglycopenia and inappropriately elevated insulin concentrations that occur primarily in the postprandial state. Both pathophysiology and treatment of this disorder remain elusive, but it has been postulated that hyperplasia and/or hypertrophy of beta-cells due to morbid obesity and/or postsurgical nesidioblastosis may contribute.
The objective of this study was to elucidate the pathophysiology of this condition; specifically, we hypothesized that metabolic abnormalities were a function of altered nutrient transit through the gastrointestinal tract rather than anatomical changes to pancreatic beta-cells that would lead to consistently high insulin secretion irrespective of nutrient transit route. DESIGN/SETTING/SUBJECT/OUTCOME MEASURES: We describe a unique case wherein gastrostomy tube (GT) insertion into the remnant stomach reversed neuroglycopenic symptoms. This subject was admitted to a university hospital research center for standardized measurement of glucose, insulin, and incretin hormones including glucagon-like peptide-1, gastric-inhibitory peptide, and glucagon.
Standardized liquid meal administration via GT vs. oral route demonstrated complete reversal of severe metabolic abnormalities that included hypersecretion of insulin and GLP-1.
Post-RYGB hyperinsulinemia and hypoglycemia result entirely from altered nutrient delivery rather than generalized hyperfunction of beta-cells due to presurgical hypertrophy/hyperfunction or postsurgical nesidioblastosis. These findings support the use of GT for treatment of severe cases and have implications for surgical manipulations that may reverse/prevent this condition.
Roux-en-Y 胃旁路手术后严重低血糖是一种日益被认识的病症,其特征为神经低血糖和不适当升高的胰岛素浓度,主要发生在餐后。该疾病的病理生理学和治疗仍然难以捉摸,但有人推测,病态肥胖和/或术后胰岛细胞增生症引起的β细胞增生和/或肥大可能与之相关。
本研究旨在阐明该病症的病理生理学;具体而言,我们假设代谢异常是由于胃肠道中营养物质转运的改变,而不是由于胰腺β细胞的解剖结构变化,导致无论营养物质转运途径如何,胰岛素分泌始终升高。
设计/设置/研究对象/结果测量:我们描述了一个独特的病例,胃造口管(GT)插入残胃后逆转了神经低血糖症状。该患者入住大学医院研究中心,进行标准化葡萄糖、胰岛素和肠降血糖素激素(包括胰高血糖素样肽-1、胃抑制肽和胰高血糖素)的测量。
通过 GT 与口服途径进行标准化液体餐给药,完全逆转了严重的代谢异常,包括胰岛素和 GLP-1 的过度分泌。
RYGB 后高胰岛素血症和低血糖症完全是由于营养物质输送的改变引起的,而不是由于术前肥大/功能亢进或术后胰岛细胞增生症引起的β细胞普遍功能亢进。这些发现支持使用 GT 治疗严重病例,并对可能逆转/预防这种情况的手术操作具有影响。